Print full article

Boehringer streamlines NGS through partnership

The company has expanded its collaboration with Swiss R&D firm, Genedata

Suggested Veterinary Products

An enhanced partnership between Boehringer Ingelheim and biopharmaceutical research and development (R&D) provider, Genedata, is set to automate the pharmaceutical company’s complex cell line development processes.

Boehringer has deployed Genedata Selector, a software platform, to support the application of next generation sequencing (NGS) in cell line engineering, clone selection, and adventitious agent detection workflows.

The implementation of NGS-based approaches throughout bioprocess development will streamline workflow and generate cost savings, Genedata says.

“We are very excited about our partnership with Boehringer Ingelheim,” says Genedata’s CEO, Othmar Pfannes, PhD. “Genedata is committed to supporting our customers looking to automate and digitalize their bioproduction processes by providing the most advanced and innovative technologies for organizations to maximize their return.”

Leave a Comment



Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.